Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3764212 | 0.89 | GALR1 (0.33) | GPR3 | |
| SCHEMBL520269 | 0.77 | — | — | |
| SCHEMBL3756374 | 0.68 | CA1 (0.32) | CA1CA2CA9 | |
| SCHEMBL9588739 | 0.66 | — | — | |
| SCHEMBL30533792 | 0.66 | CA1 (0.47) | GPR3CA1CA2CA9 | |
| SCHEMBL61667 | 0.66 | CA1 (0.47) | GPR3CA1CA2CA9 | |
| SCHEMBL255968 | 0.65 | GPR3 (0.46) | GPR3CA1CA2CA9 | |
| SCHEMBL3755561 | 0.62 | ADRA2A (0.35) | CA2 | |
| SCHEMBL16358849 | 0.61 | SMN1; SMN2 (0.33) | CA1CA2CA9 | |
| SCHEMBL2675124 | 0.61 | KMT2A (0.46) | GPR3CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | GPR3 3758/4885CA1 3477/4885CA2 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.